Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ptc Therapeutics (PTCT) Research & Development (2016 - 2025)

Ptc Therapeutics has reported Research & Development over the past 14 years, most recently at $133.1 million for Q4 2025.

  • Quarterly results put Research & Development at $133.1 million for Q4 2025, up 6.7% from a year ago — trailing twelve months through Dec 2025 was $455.2 million (down 14.82% YoY), and the annual figure for FY2025 was $455.2 million, down 14.82%.
  • Research & Development for Q4 2025 was $133.1 million at Ptc Therapeutics, up from $100.2 million in the prior quarter.
  • Over the last five years, Research & Development for PTCT hit a ceiling of $195.1 million in Q1 2023 and a floor of $100.2 million in Q3 2025.
  • Median Research & Development over the past 5 years was $133.8 million (2021), compared with a mean of $142.4 million.
  • Biggest five-year swings in Research & Development: skyrocketed 147.09% in 2021 and later plummeted 40.48% in 2024.
  • Ptc Therapeutics' Research & Development stood at $149.8 million in 2021, then grew by 25.93% to $188.7 million in 2022, then plummeted by 35.69% to $121.4 million in 2023, then increased by 2.82% to $124.8 million in 2024, then increased by 6.7% to $133.1 million in 2025.
  • The last three reported values for Research & Development were $133.1 million (Q4 2025), $100.2 million (Q3 2025), and $113.0 million (Q2 2025) per Business Quant data.